State Cancer Drug Legislative Implications
Will state legislation affect your market access strategies for your current or future products? How do payers interpret the legislation into organizational coverage decisions? Each state’s legislative provisions can vary related to content and subsequently the implications for a payer’s interpretation and application to drug coverage decisions.
DK Pierce is known for its deep-dive knowledge of drivers and influencers for the delivery of cancer care. This message highlights two of DK Pierce’s year-end 2017 updated reports under its DKP Critical Insights® market intelligence services, all designed to inform your market access strategies. These reports:
- Outline, in an interactive approach, access to summaries AND details of each state legislative position on cancer drug coverage and off-label cancer drug coverage
- Organize trends found across states specific to legislative content
- Identify how individual payers interpret and apply clinical compendia for drug coverage decisions
- Provide insights to help you understand variation across state legislation and across payer compendia interpretation, to build geographic market access strategies
DKP Critical Insights® Report – State Cancer Coverage Acts and Legislation
- Clarify “cancer drug coverage” and “coverage for off-label indications” provisions within state legislation
- Identify definition of and application for clinical compendia provisions
- Determine geographic variation in legislative content
- Understand how legislative provisions such as these can trump payer-based oncology drug coverage/utilization management
DKP Critical Insights® Report – Payer’s Use of Clinical Compendia for Off-Label Oncology Indications
- Learn how commercial payers approach clinical data through clinical compendia sources
- Identify the influence and preference of each of the CMS-recognized compendia
- Assess specific compendia level of evidence ratings accepted by a population of 63 commercial payers (87% of covered commercial lives)
- Receive a one-on-one technical training review on the report
Contact Amy Schroeder, RPh, Senior Consultant, or Blake Vanderbosch, MPH, Business Strategy Consultant for pricing on these and other available 2017 reports. If purchasing two or more of the DK Pierce Critical Insights ® reports, DKP staff will be available for a one-hour strategic planning session (at no charge) to help you understand the top line implications of each report, specific to your market/indication.
To learn more, contact us at info@dkpierce.net, visit our website at www.dkpierce.net, or call us at 317-873-0303.
Amy Schroeder, RPh, Senior Consultant
Contact her at amy.schroeder@dkpierce.net or (317) 873-0303 ext. 212.
Blake Vanderbosch, MPH, Business Strategy Consultant
Contact him at blake.vanderbosch@dkpierce.net or (317) 873-0303 ext. 213.
